LLY
Eli Lilly and Company
LLY has the edge over TVTX overall, supported by stronger fundamentals and lower modeled downside.
TVTX
Travere Therapeutics, Inc.
TVTX's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TVTX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Healthy | |
| Strong |
TVTX's revenue, cash flow and balance sheet are currently healthy, but its profitability is weak.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TVTX PE Valuation
TVTX has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 18x next year's earnings.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TVTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect TVTX to return to profit, with revenue growing. However, they disagree widely on these estimates.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TVTX on earnings quality, reporting a profit while its opponent remains loss making.
TVTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.94 | — |
| Q3 2026 | -$1.28 | -$0.24 |
| Q2 2026 | -$0.45 | +$1.57 |
| Q1 2026 | -$0.22 | +$2.57 |
| Q4 2025 | -$0.29 | +$3.79 |
| Q3 2025 | -$1.04 | +$3.51 |
| Q2 2025 | -$2.02 | -$0.14 |
| Q1 2025 | -$2.79 | -$0.69 |
| Q4 2024 | -$4.08 | -$2.47 |
TVTX is still losing money, but far less than before: $1.28 per share over the past year, against $4.56 at its worst in late 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TVTX on profitability, with a higher operating margin.
TVTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $224.6M | +36% |
| Q2 2026 | $169.6M | +48% |
| Q1 2026 | $127.2M | +56% |
| Q4 2025 | $129.7M | +73% |
| Q3 2025 | $164.9M | +162% |
| Q2 2025 | $114.4M | +111% |
| Q1 2025 | $81.7M | +98% |
| Q4 2024 | $74.8M | +66% |
TVTX has the edge over LLY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | -45 points |
| Q2 2026 | 2.3% | +13 points |
| Q1 2026 | -29% | +23 points |
| Q4 2025 | -25% | +56 points |
| Q3 2025 | 15% | +104 points |
| Q2 2025 | -11% | +114 points |
| Q1 2025 | -52% | +284 points |
| Q4 2024 | -81% | +128 points |
TVTX's operating margin was −30% last quarter, down 45 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with TVTX at up 168%.
TVTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$40.4M | +$1.8M |
| Q4 2025 | $60.7M | +$96.4M |
| Q3 2025 | $14.2M | +$56.7M |
| Q1 2025 | -$42.2M | +$76.8M |
| Q4 2024 | -$35.7M | +$34.8M |
| Q2 2024 | -$40.3M | +$29M |
| Q1 2024 | -$119M | -$37.3M |
| Q4 2023 | -$70.5M | -$15.8M |
TVTX's free cash flow has turned positive after five years mostly in the red: $93M over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TVTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.1M shares |
| 1 year | -7.8% | -8M shares |
| 3 years | +24% | +18.3M shares |
| 5 years | +56% | +33.8M shares |
| Available history | +123% | +52.3M shares |
TVTX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TVTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -5.1x | Net Cash |
| Q1 2026 | -4.9x | Net Cash |
TVTX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TVTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.4 | Neutral |
| Stochastic | 18.2 | Oversold |
TVTX's weekly RSI is 48 (neutral) and its Stochastic is 18 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TVTX PE vs Healthcare Sector
TVTX has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TVTX on trend strength, trading above more of its moving averages.
TVTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.5 | 1.7% below |
| 20 week MA | $57.6 | 11% below |
| 50 week MA | $45.2 | 14% above |
| 100 week MA | $32.9 | 57% above |
| 200 week MA | $22.8 | 126% above |
TVTX has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 126% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TVTX on returns for 2026, with the stronger performance.
TVTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.4 | $27.6 | +92% |
| 2021 | $27.6 | $31.2 | +13% |
| 2022 | $31.2 | $20.0 | -36% |
| 2023 | $20.0 | $8.99 | -55% |
| 2024 | $8.99 | $17.3 | +92% |
| 2025 | $17.3 | $39.6 | +129% |
| 2026 YTD | $39.6 | $51.6 | +30% |
TVTX's yearly returns have swung widely, from +129% in 2025 to −55% in 2023. It's up 30% so far in 2026.